These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8112406)

  • 41. Dapagliflozin and xanthine oxidase inhibitors improve insulin resistance and modulate renal glucose and urate transport in metabolic syndrome.
    Ng HY; Leung FF; Kuo WH; Lee WC; Lee CT
    Clin Exp Pharmacol Physiol; 2021 Dec; 48(12):1603-1612. PubMed ID: 34407232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver.
    Zhu JX; Wang Y; Kong LD; Yang C; Zhang X
    J Ethnopharmacol; 2004 Jul; 93(1):133-40. PubMed ID: 15182918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.
    Lü JM; Yao Q; Chen C
    Biochem Pharmacol; 2013 Nov; 86(9):1328-37. PubMed ID: 23994369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.
    Goldfarb DS; MacDonald PA; Gunawardhana L; Chefo S; McLean L
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1960-7. PubMed ID: 23929928
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
    Schumacher HR
    Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.
    Altan A; Shiozawa A; Bancroft T; Singh JA
    J Clin Rheumatol; 2015 Dec; 21(8):411-8. PubMed ID: 26580304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure.
    Maekawa M; Tomida H; Aoki T; Hishida M; Morinaga T; Tamai H
    Intern Med; 2014; 53(6):609-12. PubMed ID: 24633032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the urate lowering effects of allopurinol and diflunisal.
    Emmerson BT; Hazelton RA; Whyte IM
    J Rheumatol; 1987 Apr; 14(2):335-7. PubMed ID: 3599002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
    Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA
    Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
    Hosoya T; Ohno I
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S27-34. PubMed ID: 21654267
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Inhibitors of xanthine oxidoreductase].
    Okamoto K
    Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Febuxostat for prevention of gout attacks.
    Pohar S; Murphy G
    Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
    Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renierol from marine sponge Haliclona.SP.: a natural inhibitor of xanthine oxidase with hypouricemic effects.
    Wang GF; Shang YJ; Jiao BH; Huang CG
    J Enzyme Inhib Med Chem; 2008 Jun; 23(3):406-10. PubMed ID: 18569347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.